The research, led by Cédric Poyet of Stadtspital Triemli in Zurich and Marie Lork of the University Hospital of Zurich, together with colleagues from Kantonsspital Baden, Luzerner Kantonsspital and University Hospital Zurich, set out to identify molecular correlates of overall survival in muscle-invasive bladder cancer, often abbreviated MIBC. The team analyzed tumor DNA extracted from cystectomy specimens, the surgical samples obtained when the bladder is removed, from 32 patients treated at Swiss centers. The study received ethical approval from the Cantonal Ethics Committee Zurich and was conducted in accordance with the Declaration of Helsinki.

To characterize the genomic landscape of each tumor, the investigators used the FoundationOne CDx comprehensive genomic profiling platform, a targeted next-generation sequencing assay capable of detecting substitutions, insertions and deletions, copy number alterations and selected genomic instability markers across hundreds of cancer-related genes. Patients were then divided into two comparison groups based on a hard clinical endpoint: a favorable outcome group of 14 patients who survived at least 60 months after surgery, and a poor outcome group of 18 patients who survived fewer than 60 months. This dichotomy allowed the researchers to ask a simple but clinically vital question: which genomic features separate long-term survivors from those who die earlier of their disease?

Across the entire cohort, the sequencing effort uncovered 279 pathogenic or likely pathogenic mutations distributed across 88 genes. The most frequently altered genes were familiar names in bladder cancer biology: TP53, the guardian-of-the-genome tumor suppressor whose inactivation is a near-universal event in this disease; PIK3CA, a signaling kinase driving PI3K pathway activation; KDM6A, a histone demethylase involved in chromatin regulation; and FGFR3, a receptor tyrosine kinase that is a well-established oncogenic driver and drug target in urothelial carcinoma. Perhaps surprisingly, the distributions of these frequent alterations were similar between the favorable and poor outcome groups, indicating that the presence or absence of these canonical mutations alone does not explain the dramatic survival differences observed in the clinic.

The team next turned to the standard quantitative indicators of genomic instability that have been proposed as prognostic and predictive biomarkers in many tumor types. Tumor mutational burden, or TMB, reflects the total number of somatic mutations carried by a tumor and is widely used as a proxy for responsiveness to immune checkpoint inhibitors. Microsatellite instability, or MSI, marks defects in DNA mismatch repair and carries prognostic and predictive significance in colorectal and several other cancers. In this MIBC cohort, however, both metrics were comparable between the long-term survivors and the poor outcome group, and neither proved prognostically informative. The finding is a caution against assuming that biomarkers validated in other cancers will translate directly to bladder cancer.

The decisive signal emerged from a different layer of genomic complexity: copy number alterations. Tumors from the poor outcome group exhibited a significantly higher frequency and burden of gene amplifications, events in which segments of DNA containing particular genes are copied multiple times, often massively, driving overexpression of the encoded proteins. Crucially, these amplifications frequently involved known oncogenes and co-amplification hotspots, regions of the genome where neighboring growth-promoting genes are gained together in a single event. In other words, patients whose tumors carried a heavy load of oncogene amplifications were disproportionately represented among those who died within five years of cystectomy.

The biological logic behind this observation is compelling. While point mutations typically disable tumor suppressors or alter the function of a single protein, amplifications act as gene dosage escalators, flooding tumor cells with growth factor receptors, signaling kinases and cell cycle accelerators. High-level amplification of oncogenes can simultaneously promote proliferation, survival under therapeutic stress and metastatic competence. Moreover, co-amplification events can deliver several oncogenic payloads at once, creating tumors that are intrinsically more aggressive and harder to eradicate with a single targeted agent. The Swiss findings suggest that this dosage-driven mode of tumor evolution may be a hallmark of the most lethal forms of MIBC.

The results also carry therapeutic implications. Amplified oncogenes are, in principle, druggable targets. FGFR inhibitors are already approved for metastatic urothelial carcinoma in tumors with FGFR alterations, and agents directed against amplified receptor kinases and downstream signaling nodes are in clinical development across many cancer types. If the association between amplification burden and poor survival is confirmed, comprehensive copy number profiling at the time of cystectomy could help identify patients who warrant intensified treatment, such as perioperative systemic therapy escalation, enrollment in targeted therapy trials or closer surveillance for recurrence. Conversely, the lack of prognostic value for TMB and MSI in this cohort suggests that these markers should not be relied upon in isolation for outcome prediction in MIBC.

The authors are careful to frame the study as exploratory, and the caveats are substantial. The cohort comprised only 32 patients, divided into groups of 14 and 18, a sample size that limits statistical power and leaves open the possibility of confounding by clinical factors such as stage, nodal status and treatment sequence, which the abstract does not address in detail. The use of a targeted panel, while broad, does not capture the full spectrum of structural variants and noncoding alterations that whole-genome sequencing would reveal. The authors explicitly call for validation in larger cohorts to determine whether oncogene amplifications can serve as robust prognostic markers and to explore their potential as therapeutic targets. It is also worth noting that Roche funded the genomic testing through the FoundationOne CDx platform but had no role in study design, data analysis, interpretation or manuscript writing, apart from being granted the opportunity to review the manuscript prior to submission.

Even with these limitations, the study adds an important dimension to the ongoing effort to bring precision oncology to bladder cancer. The field has long focused on the mutational catalog of urothelial carcinoma, one of the most heavily mutated of all common tumors, yet this work suggests that the architecture of copy number gains may carry at least as much prognostic weight as the mutation list itself. For patients facing cystectomy, a procedure with significant morbidity and a five-year survival that remains unsatisfactory for many, any molecular signal that reliably separates indolent from lethal disease is valuable. If larger studies confirm that oncogene amplification burden predicts poor overall survival, clinicians may one day sequence not just for mutations but for the sheer number of oncogene copies a tumor carries, using that information to triage patients toward more aggressive, and hopefully more effective, treatment strategies from the moment of diagnosis.

Subject of Research: Genomic profiling of oncogene amplifications as prognostic markers of overall survival in muscle-invasive bladder cancer

Article Title: Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)

Article References: Poyet, C., Franzen, A. S., Bieri, U., Kaufmann, E., Eberli, D., Schmid, M., Zoche, M., Moch, H., & Lork, M. (2026). Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC). Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06626-2

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06626-2

Keywords: muscle-invasive bladder cancer, oncogene amplifications, genomic profiling, tumor mutational burden, microsatellite instability, TP53, FGFR3, PIK3CA, copy number alterations, prognostic biomarkers, cystectomy, FoundationOne CDx

Circulating tumor DNA refers to tiny fragments of cancer-derived DNA that circulate freely in a patient’s bloodstream. Its detection after surgery indicates minimal residual disease (MRD), a state where microscopic tumor cells persist and could eventually drive cancer relapse. Traditionally, clinicians lacked robust tools to identify MRD, leading to a one-size-fits-all approach in post-operative treatment. The IMvigor011 trial utilized a highly personalized ctDNA assay, with blood samples screened every six weeks for up to a year following surgery. This rigorous monitoring enabled researchers to classify patients into ctDNA-positive or ctDNA-negative groups, guiding targeted immunotherapeutic intervention.

Atezolizumab functions by blocking PD-L1, a protein frequently overexpressed on cancer cells that suppresses the immune system’s ability to recognize and attack tumors. By inhibiting this checkpoint, atezolizumab effectively unmasks cancer cells, allowing T cells to mount an immune response. While previous studies, including the IMvigor010 trial, tested atezolizumab in unselected MIBC patients post-surgery, they failed to demonstrate a clear overall survival benefit. Retrospective analyses suggested that this lack of effect was due to the inclusion of patients without residual disease who were unlikely to benefit from immunotherapy, highlighting the need for better patient stratification.

In IMvigor011, 800 patients with no clinical evidence of disease following surgery were enrolled and subjected to personalized ctDNA testing every six weeks. Approximately 250 patients who tested positive for ctDNA were randomized to receive either atezolizumab or placebo in a 2:1 ratio. Strikingly, patients receiving atezolizumab demonstrated a 36% reduction in the risk of disease recurrence compared to placebo. More impressively, the risk of death was reduced by 41% among ctDNA-positive patients receiving the immunotherapy, a landmark finding in the context of adjuvant treatments for MIBC.

Another vital insight from the trial was that ctDNA screening captured patients with residual disease regardless of when ctDNA positivity emerged—from immediately post-surgery or during subsequent surveillance within the first year. This dynamic ability to identify MRD highlights the utility of ctDNA as a real-time biomarker, refining treatment decisions dynamically and enabling clinicians to escalate or withhold therapy based on evolving risk profiles.

Equally important was the observation that ctDNA-negative patients, who did not receive immunotherapy, experienced excellent outcomes. Approximately 89% remained disease-free and over 90% were alive at a median follow-up of 21.8 months without additional treatment. This finding confirms that ctDNA negativity reliably identifies patients with a low risk of recurrence, creating an opportunity to avoid overtreatment and the associated financial and physical burdens.

The absence of new or unexpected adverse effects in the atezolizumab-treated cohort reinforces the safety of this approach when guided by ctDNA stratification. Given the immune-related toxicities known for checkpoint inhibitors, such selective treatment minimizes unnecessary exposure among those unlikely to benefit. This targeted methodology exemplifies personalized medicine’s promise by matching treatment intensity with individual patient biology.

Dr. Joaquim Bellmunt, co-principal investigator and director of the Bladder Cancer Center at Dana-Farber, emphasized the clinical significance: “This is the first adjuvant immunotherapy trial that has demonstrated a survival benefit for patients selected by ctDNA testing. It marks a pivotal step towards precision oncology where therapeutic decisions are no longer ‘one size fits all’ but are tailored to the molecular fingerprints of residual disease.”

The implications for regulatory frameworks and clinical guidelines are profound. Regulatory agencies are currently evaluating whether ctDNA-guided use of atezolizumab should become the new standard of care for MIBC patients after surgery. Adoption of such biomarkers into routine practice could redefine oncological workflows by embedding minimally invasive blood-based diagnostics as decision-making tools for adjuvant therapies.

This study was funded by F. Hoffmann-La Roche Ltd, with collaboration from Natera, a leader in ctDNA assay development. The partnership underscores the critical role of industry-scientific collaboration in rapidly translating molecular diagnostics into clinical impact.

Dana-Farber Cancer Institute, known for its integrative approach to cancer treatment and research, continues to pioneer innovations that bridge laboratory discoveries with patient care. Its involvement in trials like IMvigor011 reinforces its mission to reduce the global cancer burden through scientific inquiry and compassionate, evidence-based care.

In summary, the IMvigor011 trial charts a new course in bladder cancer therapy by harnessing the precision of ctDNA to focus immunotherapy on patients most likely to benefit. This approach offers hope for improved survival while preserving quality of life, setting a precedent for similar strategies in other malignancies where minimal residual disease detection and targeted therapy can intersect to optimize outcomes.

Subject of Research: Muscle-invasive bladder cancer, circulating tumor DNA-guided immunotherapy

Article Title: ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

News Publication Date: 20-Oct-2025

Web References:
ESMO 2025 Congress Presentation
New England Journal of Medicine Article

References:
IMvigor011 Phase 3 Clinical Trial Data, Dana-Farber Cancer Institute et al., NEJM, 2025

Image Credits: Dana-Farber Cancer Institute

Keywords: Cancer, Muscle-invasive bladder cancer, Circulating tumor DNA, Immunotherapy, Atezolizumab, Minimal residual disease, Precision oncology

Bladder cancer that invades the muscle wall represents a particularly pernicious form of the disease, frequently necessitating radical cystectomy—a surgical procedure involving complete removal of the bladder. Despite this aggressive surgical intervention, relapse within the pelvic region remains alarmingly common, occurring in up to one-third of patients within two to three years post-operation. The challenge has prompted oncologists to explore avenues for improving local disease control, enhancing quality of life, and ultimately improving survival outcomes. Radiation oncologist Vedang Murthy, MD, and his team spearheaded a comprehensive investigation into whether post-operative radiation could fill this therapeutic void.

The BART trial enrolled 153 patients harboring high-risk, muscle-invasive urothelial carcinoma of the bladder. These individuals were randomized in nearly equal proportions to receive either adjuvant radiation therapy following cystectomy or undergo observation alone. Patients in both cohorts received standard chemotherapy regimens either prior to surgery or in the postoperative setting, reflecting contemporary multimodal treatment approaches. The radiation protocol delivered 50.4 Gray (Gy) across 28 fractions using advanced IMRT technology, enabling precise targeting of the pelvic surgical bed while sparing surrounding healthy tissues, thus minimizing toxicity.

Results from a median follow-up period of 47 months unveil a striking reduction in pelvic recurrences with the use of adjuvant radiation. Only 8% of patients receiving radiation experienced locoregional relapse compared to 26% in the observation group, a difference reaching robust statistical significance. The primary endpoint—two-year locoregional recurrence-free survival—was markedly improved, with 91.2% of irradiated patients remaining free from pelvic relapse versus 76.4% in the control arm. These data underscore the capacity of radiation to deliver sustained local disease control where surgery and chemotherapy alone have proven insufficient.

Importantly, the study demonstrated that the addition of radiation did not exacerbate severe side effects. Both early and late toxicities were comparably low across treatment arms, with severe late adverse events occurring in under 10% of patients regardless of radiation exposure. This finding substantiates the enhanced safety profile of modern radiation delivery techniques, particularly IMRT, which allows modulation of radiation beams to conform tightly to the complex anatomy of the pelvic region, reducing collateral damage to critical structures.

The trial cohort comprised a particularly high-risk population, with most patients exhibiting advanced pathological features such as extravesical tumor extension (pT3–T4), lymph node positivity (pN+), and variant histological subtypes, all markers historically associated with poor prognosis. In subgroup analyses, those with larger tumors and nodal involvement appeared to derive greater benefit from adjuvant radiation, pointing toward a personalized approach in selecting patients most likely to gain from radiation therapy after cystectomy.

While disease-free survival—a measure inclusive of recurrence anywhere in the body—also trended favorably with radiation, the difference did not reach conventional thresholds for statistical significance. Notably, incidence rates of distant metastases remained similar between groups, affecting approximately one-third of patients. This observation highlights the systemic nature of muscle-invasive bladder cancer, emphasizing that while radiation robustly controls pelvic disease, advancements in systemic therapies are crucial to combat distant spread.

Overall survival at two years was higher in the radiation arm, but again without reaching statistical significance, an outcome likely influenced by the limited sample size inherent to the trial. Dr. Murthy acknowledges this limitation and points toward ongoing international collaborations aimed at pooling data to yield more definitive conclusions regarding survival benefits.

The BART trial distinguishes itself as one of the largest and most rigorously conducted studies exploring post-operative radiation in bladder cancer. It addresses a critical unmet need in oncology by validating that radiation, when applied with modern techniques, can be integrated safely into the treatment paradigm without compromising patient well-being. This represents a paradigm shift, as radiation therapy has traditionally been underutilized in this context, partly due to historical concerns regarding toxicity and uncertain efficacy.

Looking forward, a pivotal research avenue involves investigating the synergy between radiation therapy and immunotherapy—now a front-line option for muscle-invasive bladder cancer. Immunotherapeutic agents, including immune checkpoint inhibitors, have revolutionized oncology by harnessing the patient’s immune system to recognize and destroy cancer cells. Combining these systemic therapies with targeted radiation may enhance anti-tumor immune responses, potentially improving both local and systemic control. Dr. Murthy emphasizes the necessity of prospective trials exploring such combinations, given their distinct mechanisms of action and non-overlapping toxicities.

The BART trial’s findings resonate beyond bladder cancer care, affirming the growing role of precision radiation delivery in oncology. IMRT and other advanced modalities represent powerful tools capable of safely expanding the therapeutic arsenal against cancers located in anatomically complex regions. Drawing parallels to gynecologic oncology, where post-operative radiation is established as standard practice, the inclusion of radiation in high-risk bladder cancer management appears both logical and feasible.

In summary, this pioneering study confirms that adjuvant radiation therapy can substantially reduce pelvic relapse in patients with locally advanced, muscle-invasive bladder cancer post-cystectomy, without adding undue toxicity. While distant metastases remain a formidable challenge, improved local control is expected to translate into better quality of life and may ultimately impact survival when combined with emerging systemic therapies. As the oncology community awaits further data from expanded meta-analyses and combination treatment trials, the BART trial sets a new benchmark and calls for a reassessment of treatment guidelines to incorporate radiation therapy more actively in managing this devastating disease.

Subject of Research: Locally advanced, muscle-invasive bladder cancer and adjuvant radiation therapy

Article Title: Post-operative Radiation Therapy Dramatically Reduces Pelvic Relapse in High-risk Muscle-Invasive Bladder Cancer: Insights from the BART Phase III Trial

News Publication Date: September 29, 2025

Web References:
– American Society for Radiation Oncology (ASTRO) Annual Meeting: http://www.astro.org/annualmeeting
– BART Trial Abstract: https://amportal.astro.org/sessions/pl-01-21644/bladder-adjuvant-radiotherapy-bart-clinical-outcomes-from-a-phase-iii-multicenter-randomized-109076
– Vedang Murthy MD Bio and Disclosures: https://amportal.astro.org/vedang-murthy-md-135213513

References:
– Murthy V, et al. Intensity-modulated radiation therapy after cystectomy in muscle-invasive bladder cancer: safety and clinical outcomes. Red Journal. [https://www.redjournal.org/article/S0360-3016(24)03411-4/fulltext]

Keywords: Cancer, Radiation therapy, Muscle-invasive bladder cancer, Clinical trials, Oncology, Adjuvant therapy